Project Grant R37CA289981
Award Date
6/1/25
Completion Date
4/30/30
Dollars Obligated
$456K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
This $503,194 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Seattle Children's Hospital aims to develop a multispecific T cell engager (MTE) therapy to treat neuroblastoma and other pediatric solid tumors. The key objectives are to: 1) Determine the vulnerability of patient-derived neuroblastomas to the MTE therapy that targets ROR1 and PD-L1, and 2) Evaluate the MTE's efficacy in pediatric tumors with varying ROR1 expression. This...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the Dana-Farber Cancer Institute, Inc. (DFCI) to improve survival for children with diffuse midline gliomas (DMG), a rare and deadly type of brain cancer. The $1,243,002 award aims to enhance the efficacy of radiotherapy for DMG by exploiting synthetic lethal vulnerabilities. Key objectives include: Testing the hypothesis that combining radiation with antagonists of...
This Project Grant award for $616,710.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the Children's Research Institute in Washington, D.C. in designing effective adoptive immunotherapy for high-risk pediatric medulloblastoma. The research aims to develop a rational combination with MRI-guided focused ultrasound technology to enhance this innovative cancer treatment approach. The award period runs from August 1, 2024...
The federal Project Grant award of $447,831 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Colorado-Denver supports the development of chimeric antigen receptor (CAR) phagocytes for the treatment of glioblastoma, a type of pediatric high-grade glioma (PHGG). The 5-year project, commencing on July 1, 2024, aims to investigate innovative immunotherapeutic approaches to combat this aggressive form of brain cancer. The research will focus on...
The National Cancer Institute (NCI) awarded a 5-year, $289,458 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to St. Jude Children's Research Hospital Inc. The funding will support a research program focused on developing novel CD19-CAR T-cell therapies to improve outcomes for pediatric patients with relapsed and/or refractory B-cell acute lymphoblastic leukemia (B-ALL). The key objectives include: Conducting a Phase I clinical trial to evaluate an allogeneic CD19-CAR...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $708,100 Project Grant to the Dana-Farber Cancer Institute, Inc. (Dfci) to conduct research on "Overcoming Rebound Growth of Pediatric Low-Grade Glioas Following MAPK Pathway Inhibition." The grant, which runs from July 1, 2024 to June 30, 2026, will support Dfci's efforts to better understand the mechanisms driving recurrence of pediatric low-grade glioma brain tumors after...
This $249,645 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) to The Children's Hospital Corporation (Boston Children's Hospital) aims to develop a novel immunotherapy strategy using gene-edited, tumor-specific B cells. The goal is to leverage the tumor-suppressing and immune-stimulating functions of these engineered B cells to enhance anti-cancer immunity. The project will exploit an optimized B cell gene editing protocol to redirect the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $553,167 to The Washington University to conduct a multi-institutional Phase I/II clinical trial evaluating the safety, efficacy, and immunogenicity of a peptide vaccine (PEP-CMV) in combination with checkpoint blockade therapy for the treatment of pediatric brain cancers, including diffuse midline glioma, high-grade glioma, medulloblastoma, and ependymoma. The trial aims to...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports the development of a "next-generation" precision adoptive T cell therapy approach for the treatment of pediatric high-grade gliomas. The $474,656 award, which runs from August 2024 to July 2029, will enable the University of Florida to: 1) evaluate the safety, efficacy, and immunologic effects of this precision ACT targeting neoantigens and tumor-associated antigens in...
This $159,636 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) aims to investigate the use of targeted radionuclide therapy (TRT) to enhance the efficacy of chimeric antigen receptor (CAR) T cell therapy against neuroblastoma, a deadly pediatric cancer. The principal investigator, Dr. Quaovi Sodji at the University of Wisconsin-Madison, will lead a 5-year research program to: 1) identify the optimal radiation dose from TRT that CAR T cells...